Alzheimer's Disease: Eight-Market Drug Forecast and Market Analysis

List of Tables

This report covers the 8 major markets and provides an Excel-based forecast model for the Alzheimer's Disease market through 2033.

GlobalData estimates that the value of the Alzheimer's Disease (AD) market in the 8MM in 2023 was $2.4 billion. This market is defined as sales of symptomatic and disease modifying (DMT) treatments including approval of anti-AB monoclonal antibodies (mAbs) across the 8MM (US, France, Germany, Italy, Spain, UK, Japan and China). The US and China markets make up the majority of total global sales, contributing $1.1 billion (44.7%) and $915.2 million (38.8%), respectively. The smallest market is France, contributing only 1.1% to total global sales, due to the lower AD prevalent population in the country, as well as the lack of reimbursement of the current AD symptomatic therapies resulting in lower treatment rates in France.

By the end of the forecast period in 2033, GlobalData projects AD sales to rise to $14.7 billion in the 8MM, at a compound annual growth rate (CAGR) of 20.0%.

Scope

Overview of Alzheimer's Disease, including epidemiology, symptoms, diagnosis, and disease management.
Annualized Alzheimer's Disease therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the Alzheimer's therapeutics market.
Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for Alzheimer's treatment. The most promising candidates in late-stage development are profiled.
Analysis of the current and future market competition in the global Alzheimer's Disease therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the 8MM Alzheimer's Disease therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 8MM Alzheimer's Disease therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Product Code: GDHC346PIDR-8M

List of Tables

List of Figures

1 Alzheimer's Disease: Executive Summary

1.1 Summary of changes
1.2 Executive summary
1.3 Alzheimer's market forecast to see double-digit sales growth out to 2033
1.4 Eisai, Biogen, and Lilly are forecast to lead the AD market in 2033
1.5 Opportunities to fulfil key unmet needs will remain
1.6 Novel late-stage pipeline drugs will be a key driver of growth
1.7 What Do Physicians Think?

2 Introduction

2.1 Catalyst
2.2 Related reports
2.3 Upcoming reports

3 Disease Overview

3.1 Etiology
- 3.1.1 Risk genes
- 3.1.2 Deterministic genes
- 3.1.3 Protective genes
- 3.1.4 Metabolic disruption
3.2 Pathophysiology
- 3.2.1 Structural changes in the brain
- 3.2.2 Degenerative process
- 3.2.3 AB plaques
- 3.2.4 Neurofibrillary tangles
- 3.2.5 Neurotransmitter deficiencies
- 3.2.6 Oxidative stress
3.3 Biomarkers / targets of interest
3.4 Disease staging systems
3.5 Symptoms and prognosis

4 Epidemiology

4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global and Historical Trends
4.4 Forecast Methodology
- 4.4.1 Sources
- 4.4.2 Forecast Assumptions and Methods
- 4.4.3 Forecast assumptions and methods: total prevalent cases of AD by DSM-IV criteria
- 4.4.4 Forecast assumptions and methods: total prevalent cases of AD by severity
- 4.4.5 Forecast assumptions and methods: total prevalent cases of preclinical AD
- 4.4.6 Forecast assumptions and methods: total prevalent cases of MCI
4.5 Epidemiological Forecast for AD (2023-33)
- 4.5.1 Total prevalent cases of AD by DSM-IV criteria
- 4.5.2 Age-specific total prevalent cases of AD by DSM-IV criteria
- 4.5.3 Sex-specific total prevalent cases of AD by DSM-IV criteria
- 4.5.4 Total prevalent cases of AD by severity
- 4.5.5 Total prevalent cases of preclinical AD
- 4.5.6 Age-specific total prevalent cases of preclinical AD
- 4.5.7 Sex-specific total prevalent cases of preclinical AD
- 4.5.8 Total prevalent cases of MCI
- 4.5.9 Age-specific total prevalent cases of MCI
- 4.5.10 Sex-specific total prevalent cases of MCI
4.6 Discussion
- 4.6.1 Epidemiological forecast insight
- 4.6.2 COVID-19 impact
- 4.6.3 Limitations of the Analysis
- 4.6.4 Strengths of the Analysis

5 Disease Management

5.1 Diagnosis and treatment overview
5.2 KOL insights on disease management

6 Current Treatment Options

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview
7.2 More efficacious DMTs
7.3 Improved control of behavioral symptoms
7.4 Symptomatic drugs for cognition
7.5 Improving diagnosis earlier in the disease progression
7.6 Access to treatment

8 R&D Strategies

8.1 Overview
- 8.1.1 Targeting AB
- 8.1.2 Novel MOAs
- 8.1.3 Targeting agitation and psychosis
- 8.1.4 Targeting preclinical AD
- 8.1.5 Combination therapies
- 8.1.6 Non-pharmacological treatments
8.2 Clinical Trials Design
- 8.2.1 Inclusion/exclusion criteria
- 8.2.2 Endpoints
- 8.2.3 Use of biomarkers in trial design

9 Pipeline Assessment

9.1 Overview
9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview
10.2 Competitive Assessment
- 10.2.1 Potential DMTs
- 10.2.2 Therapies for agitation and psychosis associated with AD

11 Current and Future Players

11.1 Overview
11.2 Deal-Making Trends

12 Market Outlook

12.1 Global Markets
- 12.1.1 Forecast
- 12.1.2 Drivers and barriers - global issues
12.2 US
- 12.2.1 Forecast
- 12.2.2 Key Events
- 12.2.3 Drivers and Barriers
12.3 5EU
- 12.3.1 Forecast
- 12.3.2 Key Events
- 12.3.3 Drivers and Barriers
12.4 Japan
- 12.4.1 Forecast
- 12.4.2 Key events
- 12.4.3 Drivers and barriers
12.5 China
- 12.5.1 Forecast
- 12.5.2 Key events
- 12.5.3 Drivers and barriers

13 Appendix

13.1 Bibliography
13.2 Abbreviations
13.3 AD clinical development pipeline
13.4 Methodology
- 13.4.1 Forecasting methodology
13.5 Primary research - KOLs interviewed for this report
13.6 Primary research - prescriber survey
13.7 About the authors
- 13.7.1 Analyst
- 13.7.2 Therapy Area Director
- 13.7.3 Epidemiologist
- 13.7.4 Managing Epidemiologist
- 13.7.5 Vice President of Disease Intelligence and Epidemiology
- 13.7.6 Global Head of Pharma Research, Analysis, and Competitive Intelligence
About GlobalData
Contact Us

Product Code: GDHC346PIDR-8M

List of Table

List of Tables

Table 1: Summary of changes to the Alzheimer's Disease: Eight-Market Drug Forecast and Analysis - Update Report
Table 2: Alzheimer's disease: Key metrics in the 8MM
Table 3: Categorization of fluid analyte and imaging biomarkers
Table 4: Intended uses for imaging, CSF and plasma biomarker assays
Table 5: Clinical staging for individuals on the Alzheimer's disease continuum
Table 6: The seven-stage Reisberg scale of AD
Table 7: Common symptoms of AD across three main clinical stages
Table 8: Risk factors and comorbidities for AD
Table 9: Summary of NINCDS-ARDA diagnostic criteria for AD
Table 10: Treatment guidelines for AD
Table 11: Context of use for biomarkers in AD clinical trials
Table 12: Top 10 deals by value, 2016-26
Table 13: AD market - global drivers and barriers, 2023-33
Table 14: Key events impacting sales for AD in the US, 2023-33
Table 15: AD market - drivers and barriers in the US, 2023-33
Table 16: Key events impacting sales for AD in the 5EU, 2023-33
Table 17: AD market - drivers and barriers in the 5EU, 2023-33
Table 18: Key events impacting sales for AD in Japan, 2023-33
Table 19: AD market - drivers and barriers in Japan, 2023-33
Table 20: Key events impacting sales for AD in China, 2023-33
Table 21: AD market - drivers and barriers in China, 2023-33
Table 22: AD clinical development pipeline by drug class
Table 23: High-prescribing physicians (non-KOLs) surveyed, by country

List of Figure

List of Figures

Figure 1: Global AD sales forecast by country, in 2023 and 2033
Figure 2: Analysis of the company portfolio gap in AD during the forecast period
Figure 3: Competitive assessment of the late-stage potential DMTs that GlobalData expects to be licensed for the treatment of AD during the forecast period
Figure 4: 8MM, total prevalence of AD by DSM-IV criteria (%), men and women, ages >=65 years, 2023
Figure 5: 8MM, total prevalence of preclinical AD (%), men and women, ages >=55 years, 2023
Figure 6: 8MM, total prevalence of MCI (%), men and women, ages >=65 years, 2023
Figure 7: 8MM, sources used and not used to forecast the total prevalent cases of AD by DSM-IV criteria
Figure 8: 8MM, sources used to forecast the total prevalent cases of AD by severity
Figure 9: 8MM, sources used to forecast the total prevalent cases of preclinical AD
Figure 10: 8MM, sources used to forecast the total prevalent cases of MCI
Figure 11: 8MM, total prevalent cases of AD by DSM-IV criteria, N, both sexes, ages >=65 years, 2023
Figure 12: 8MM, total prevalent cases of AD by DSM-IV criteria by age, N, both sexes, 2023
Figure 13: 8MM, total prevalent cases of AD by DSM-IV criteria by sex, N, ages >=65 years, 2023
Figure 14: 8MM, total prevalent cases of AD by severity, N, both sexes, ages >=65 years, 2023
Figure 15: 8MM, total prevalent cases of preclinical AD, N, both sexes, ages >=55 years, 2023
Figure 16: 8MM, total prevalent cases of preclinical AD by age, N, both sexes, 2023
Figure 17: 8MM, total prevalent cases of preclinical AD by sex, N, ages >=55 years, 2023
Figure 18: 8MM, total prevalent cases of MCI, N, both sexes, ages >=65 years, 2023
Figure 19: 8MM, total prevalent cases of MCI by age, N, both sexes, 2023
Figure 20: 8MM, total prevalent cases of MCI by sex, N, ages >=65 years, 2023
Figure 21: 8MM, disease management timeline for AD
Figure 22: 8MM, treatment algorithm for AD
Figure 23: Unmet needs and opportunities in AD
Figure 24: Overview of the development pipeline in AD
Figure 25: Key late-stage trials for the promising potential DMTs that GlobalData expects to be licensed for AD in the 8MM during the forecast period
Figure 26: Key late-stage trials for the promising pipeline agents that GlobalData expects to be licensed for agitation/psychosis associated with AD in the 8MM during the forecast period
Figure 27: Competitive assessment of the pipeline potential DMTs benchmarked against Leqembi (lecanemab)
Figure 28: Competitive assessment of the pipeline anti-agitation and anti-psychosis drugs benchmarked against Risperdal (risperidone)
Figure 29: Analysis of the company portfolio gap in AD during the forecast period
Figure 30: Global (8MM) sales forecast by country for AD in 2023 and 2033
Figure 31: Global (8MM) sales forecast by drug class for AD in 2023 and 2033
Figure 32: Sales forecast by class for AD in the US in 2023 and 2033
Figure 33: Sales forecast by drug class for AD in the 5EU in 2023 and 2033
Figure 34: Sales forecast by drug class for AD in Japan in 2023 and 2033
Figure 35: Sales forecast by drug class for AD in China in 2023 and 2033

Alzheimer's Disease: Eight-Market Drug Forecast and Market Analysis - Update (2026)

Description

Table of Contents

List of Tables

Scope

Reasons to Buy

Table of Contents

Table of Contents

List of Tables

List of Figures

1 Alzheimer's Disease: Executive Summary

2 Introduction

3 Disease Overview

4 Epidemiology

5 Disease Management

6 Current Treatment Options

7 Unmet Needs and Opportunity Assessment

8 R&D Strategies

9 Pipeline Assessment

10 Pipeline Valuation Analysis

11 Current and Future Players

12 Market Outlook

13 Appendix

List of Table

List of Tables

List of Figure

List of Figures